Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
23.49
+0.14 (0.60%)
At close: May 4, 2026, 4:00 PM EDT
23.61
+0.12 (0.51%)
Pre-market: May 5, 2026, 7:00 AM EDT
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 354 employees as of December 31, 2025. The number of employees increased by 12 or 3.51% compared to the previous year.
Employees
354
Change (1Y)
12
Growth (1Y)
3.51%
Revenue / Employee
$1,062,350
Profits / Employee
-$45,596
Market Cap
2.94B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 354 | 12 | 3.51% |
| Dec 31, 2024 | 342 | 46 | 15.54% |
| Dec 31, 2023 | 296 | 28 | 10.45% |
| Dec 31, 2022 | 268 | 121 | 82.31% |
| Dec 31, 2021 | 147 | 93 | 172.22% |
| Sep 30, 2021 | 143 | 90 | 169.81% |
| Jun 30, 2021 | 108 | 59 | 120.41% |
| Mar 31, 2021 | 75 | 32 | 74.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Beam Therapeutics | 511 |
| Denali Therapeutics | 503 |
| Tarsus Pharmaceuticals | 370 |
| Dyne Therapeutics | 258 |
| Alumis | 224 |
| Structure Therapeutics | 220 |
| Soleno Therapeutics | 182 |
| Immunome | 177 |
ARQT News
- 7 days ago - Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months - GlobeNewsWire
- 12 days ago - Arcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines - GlobeNewsWire
- 19 days ago - Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 - GlobeNewsWire
- 20 days ago - Arcutis Biotherapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 4 weeks ago - Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 6 weeks ago - Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 7 weeks ago - Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology - GlobeNewsWire